HIV VACCINE

摘要

A glycoconjugate for use in treating or preventing an HIV infection or AIDS, wherein the glycoconjugate comprises an oligosaccharide group which is linked to a carrier protein, wherein the oligosaccharide group is of formula (I): wherein: M3 is a modified mannose unit; each M2 is the same or different and represents a mannose unit or a modified mannose unit; - M1 represents a mannose unit or a modified mannose unit, and the oligosaccharide moiety is linked to the carrier protein via M1; p is 0, or 1; q is 0 or 1; S1 is a saccharide unit or a modified saccharide unit; - r, s and t are zero or an integer from 1 to 5, wherein at least two of r, s and t are zero; wherein the or each modified mannose unit or modified saccharide unit is a mannose unit or saccharide unit having one or more modifications, the or each modification being independently selected from modifications A and B, wherein: modification A is replacement of a hydrogen atom of the mannose unit or saccharide unit with a C1 -3 alkyl group optionally substituted with a hydroxyl group; and modification B is replacement of a hydroxyl group of the mannose unit or saccharide unit with a hydrogen atom.